A Multi- Omics Analysis of GPC3 Down-Expression linking Poor Clinical Outcomes in Human Lung Adenocarcinoma

computer science

Description

A Multi- Omics Analysis of GPC3 Down-Expression linking Poor Clinical Outcomes in Human Lung Adenocarcinoma

or

Down-Expression of GPC3 Tumor Suppressor Gene and Its Prognostic Clinical Outcomes in Human Lung Adenocarcinoma via Bioinformatics Approaches / Multi-Omics Analysis

or

Downregulation of GPC3 Is A Predictor of Poor Prognosis in Human Lung Adenocarcinoma

 

Sharmin Aktar1α, Niaz Morshed2α, Rumana Mahtarin3α, Raihan Rahman Imon4, Anindo Rahman4

 

1Department of Microbiology, University of Dhaka, Bangladesh

2Department of Pharmacy, University of Dhaka, Bangladesh

3Department of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet-3114, Bangladesh

4Department of Genetic Engineering and Biotechnology, Jashore University of Science & Technology, Jashore, Bangladesh;

E-Mail: [email protected] (S.A.), [email protected] (N.M.), [email protected] (R.M.)

Correspondence:

 αThese authors contributed equally to this study.

 

 

Abstract: Lung adenocarcinoma is a major cause of death worldwide. Some evidence for loss of GPC3 expression has been reported in lung cancer. GPC3, a membrane-bound proteoglycan whose expression has been associated with malignancies due to both mutations and atypical protein expression. In this study, applying multi-omics approaches, we systematically explored the expression of GPC3 and its clinical outcome in lung adenocarcinoma (LUAD) via widely accessible cancer gene expression and patient survival data through various bioinformatics databases. To observe the variations of GPC3 expression between various cancers and their normal tissues, we employed the Oncomine, GEPIA2, UALCAN databases. The incidence of mutations and copy number alterations of GPC3 were explored with cBioPortal. The co-expression profile of GPC3 in LUAD was exposed via Oncomine. The most co-expressed gene along with GPC3 downregulation was FHL1, tumor suppressor. It emphasized that GPC3 was identified as a tumor suppressor in our study, eventually, GPC3 mRNA and protein levels in LUAD were significantly reduced than those in normal lung tissue. Prognoscan analysis curve revealed the downregulation of GPC3 expression, which was significantly correlated with poor survival in patient.  The pathway and gene ontology investigation were done using co-expressed genes along with GPC3 via the PANTHER web tool to search the anticipated signaling pathways in LUAD. Overall, our data recommend that GPC3 might be a prognostic novel biomarker for therapeutics improvement in LUAD. 

Instruction Files

Related Questions in computer science category